candeltx.com - CADL Operating profit EBITDA
Candel Therapeutics (CADL) operations are protected by the humanitarian status of medicine and the stable US ecosystem. The EBITDA trajectory visualizes the actual financial strength of the business, where the 0.00 mark indicates the current state of profit. Growth potential relies on the commercialization of drugs for solid tumors. The CandeVax platform, which utilizes viral vectors for the targeted destruction of cancer cells, provides a competitive advantage.
Candel Therapeutics, Inc. (CADL) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Equity Ratio Candel Therapeutics|CADL - Long-Term Debt to Capital|Short-Term Debt to Capital Candel Therapeutics Inc.|CADL - Company Debts|Debt to Book Value Ratio Candel Therapeutics|CADL - Company Long-Term Debts|Company Short-Term Indebtedness Candel Therapeutics|Immediate Liquidity candeltx.com
- earnings and market ratios statistics:
CADL - Company Net Income|Expected Profit Candel Therapeutics|CADL - Price to Earnings Ratio|Future Price to Earnings Multiple Candel Therapeutics Inc.|CADL - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Candel Therapeutics|CADL - Operating profit EBITDA|Earnings per share for the trailing year Candel Therapeutics|CADL - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months candeltx.com|CADL - Earnings per share growth in current year|Expected earnings per share trend next year Candel Therapeutics
Analysis of all company metrics:Candel Therapeutics - CADL
Future revenues for Candel Therapeutics (CADL) depend on the successful market launch of the CAN-2409 platform oncology drugs for the treatment of brain and prostate cancer. The trend in the company's total operating profit allows for the tracking of real cash flow volumes without quarterly lags, helping investors identify the true business trend and avoid purchasing the asset at a local peak ahead of a potential correction.
Who Candel Therapeutics competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit EBITDA PSNL|Operating profit before deduction of amortization erasca.com ERAS|Operating profit EBITDA DCTH (Delcath Systems)|Operating profit EBITDA Y-mAbs Therapeutics Inc YMAB|AURA - Profit before payment of interest, taxes and amortization|ARAY (Accuray, Inc.) - Operating profit before amortization|SLS: Operating profit EBITDA|Operating profit before amortization ACTU|CTOR (Citius Oncology) - Operating profit EBITDA|Profit before interest, taxes and amortization TuHURA HURA|Profit before payment of interest, taxes and amortization Protara (TARA)|Profit before payment of interest, taxes and amortization FATE (Fate Pharma)|Aadi Bioscience - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization TCRX|CSBR: Operating profit before deduction of amortization|XBiotech Inc. - Company profit before taxes, interest and amortization|CVM: Operating profit EBITDA|OS Therapies, Inc. - Income before deduction of interest, taxes and amortization|RADX (Radiopharm Theranostics) - Operating profit EBITDA|Profit before interest, taxes and amortization Artiva ARTV|Profit before payment of interest, taxes and amortization Adlai Nortye Ltd. (ANL)|VERU (Veru Inc) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA TPST (Tempest Tx)|Operating profit EBITDA Xilio Therapeutics Inc XLO|RENB - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization MURA|KAPA: Operating profit EBITDA|Profit before interest, taxes and amortization OnKure Therapeutics (OKUR)|Operating profit before deduction of amortization GDTC|Operating profit EBITDA Curis Corp|Operating profit before deduction of amortization APLM (Apollomics, Inc.)|Company profit before taxes, interest and amortization THAR|Operating profit EBITDA ADVB (Advanced Biomed)|Operating income before deduction of amortization Genprex Inc. (GNPX)|Calidi Bio - Operating profit EBITDA|sunshinebiopharma.com (SBFM) - Operating profit before deduction of amortization|xeneticbio.com (XBIO) - Profit before payment of interest, taxes and amortization|SLRX - Operating income before deduction of amortization|PPBT (Purple Biotech Ltd.) - Operating profit EBITDA|Operating profit before deduction of amortization AON (AONC)|Operating profit EBITDA BGNE|Operating profit EBITDA Checkpoint Therapeutics Inc (CKPT)|Operating profit EBITDA ELEV (Elevation Oncology)|ICAD: Operating profit before amortization|IKNA - Profit before payment of interest, taxes and amortization|NTBL: Profit before payment of interest, taxes and amortization|VIRX: Operating profit EBITDA|Operating profit before deduction of amortization MorphoSys Corporation|NAYA (NAYA Biosciences) - Operating profit EBITDA|Operating profit EBITDA ascentage.com
